中文名称: | Conoidin A | ||||
---|---|---|---|---|---|
英文名称: | Conoidin A | ||||
别名: | 1,4-二氧代-2,3-二溴甲基喹啉 2,3-Bis(bromomethyl)quinoxaline 1,4-dioxide;2,3-bis(bromomethyl)-4-oxidoquinoxalin-1-ium 1-oxide;Conoidin A;2,3-Bis-brommethyl-chinoxalin-1,4-dioxid | ||||
CAS No: | 18080-67-6 | 分子式: | C10H8Br2N2O2 | 分子量: | 347.99 |
CAS No: | 18080-67-6 | ||||
分子式: | C10H8Br2N2O2 | ||||
分子量: | 347.99 |
基本信息
产品编号:C10790 |
|||||
产品名称:Conoidin A |
|||||
CAS: |
18080-67-6 |
储存条件 |
粉末 |
2-8℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
两年 |
||
分子量 |
347.99 |
-20℃ |
一个月 |
||
化学名: |
|||||
Solubility (25°C) |
体外 |
DMSO |
70mg/mL (201.15mM) |
||
Ethanol |
Insoluble |
||||
Water |
Insoluble |
||||
体内 |
现配现用 |
|
|||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
2.8736mL |
14.3682mL |
28.7365mL |
5mM |
0.5747mL |
2.8736mL |
5.7473mL |
10mM |
0.2874mL |
1.4368mL |
2.8736mL |
50mM |
0.0575mL |
0.2874mL |
0.5747mL |
生物活性
产品描述 |
刚地弓形虫过氧化物酶 II (TgPrxII) 的细胞通透性抑制剂。 |
|
靶点/IC50 |
T.gondii enzyme peroxiredoxin II (TgPrxII) IC50: 23µM |
|
体外研究 |
Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer.Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity in vitro. Conoidin A also shown toalkylate or crosslink catalytic cysteines of wild type AcePrx-1 in Ancylostoma ceylanicum and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII.Conoidin A (5µM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II. |
|
体内研究 |
Conoidin A (intraperitoneal injection; 5mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HYN0162) on the ST‐segment elevation. Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐treatment with conoidin A abolishs the effect of Luteolin. Pre‐treatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDH in vivo. |
|
Animal Model: |
Rat myocardial I/R model |
|
Dosage: |
5mg/kg |
|
Administration: |
Intraperitoneal injection; 5mg/kg; for three successive days before MI/R injury |
|
Result: |
Intraperitoneal injection; 5mg/kg; for three successive days before MI/R injury |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )